2024 saw a sharp revenue decline and a net loss due to lower respiratory product sales, inventory write-downs, and high R&D costs. Cardiovascular products remained the main revenue driver, while overseas sales grew modestly. The company will focus on cost control and innovation in 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.